Stockhouse.com did a large in-depth deep dive on InMed. We think it is definitely work checking it out. Below is an excerpt:
---
Stockhouse investors have already seen a preview of InMed Pharmaceuticals Inc. (CSE: IN, OTCQB: IMLFF, Forum), an emerging cannabis bio-pharma company. In a recent feature article, readers were informed that IN had just closed on a $5.75 million financing – led by investment banks like Canaccord Genuity and Roth Capital Partners.
These Investment Banks have underwritten the deals of some of the largest players in the entire bio-pharma space, corporations like GW Pharmaceuticals ($2.6 billion market cap) and Zynerba ($250 million). So, what was the interest of these major players in doing an underwritten financing for relatively tiny InMed Pharmaceuticals, with (at present) a market cap of $41 million?
What immediately shines through with this bio-pharma gem is intellectual property. To appreciate this business model requires taking a step back to look at The Big Picture.
Cannabinoids are natural substances, found in abundance in the human body. The cannabinoids which are naturally produced within our bodies are known as endocannabinoids. Far from being “dangerous”, these active ingredients in the cannabis plant are essential for human health.
The cannabis plant produces more than 90 different cannabinoids, yet nearly all media and medical attention has focused on just two: tetrahydrocannabinol (THC) and cannabidiol (CBD). Why? In terms of quantity, these two cannabinoids dominate the total cannabinoid content of the cannabis plant – by a wide margin.
In contrast, over 80 of these cannabinoids are only found in trace amounts in the cannabis plant. Think of those as the cannabis equivalent of “rare earths”.
The analogy is more appropriate than many investors might think. Among the numerous chemical properties of rare earths are many potential medicinal applications. So why aren’t rare earths an important ingredient in a large number of medications? It is impossible to commercially produce these substances in great enough quantities, at a low enough price to ever make the production of such medicines feasible.
This brings us back to The Big Picture – for InMed and cannabis.
READ THE FULL STORY AT STOCKHOUSE.COM
Read More
The Bio Pharma Project Generator
